StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
ResMed (RMD) share price 'may have overcompensated' - Morgan Stanley
October 27, 2023 11:38 AM
Morgan Stanley upgraded shares of ResMed (NYSE: RMD) to Overweight from Equal-Weight, lowering the price target on the stock to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Hot List
Upgrades
Next Articles
ResMed (RMD) PT Lowered to $158 at Jefferies
October 27, 2023 7:57 AM
Morgan Stanley Upgrades ResMed (RMD:AU) (RMD) to Overweight
October 27, 2023 6:28 AM
Morgan Stanley Upgrades ResMed (RMD) to Overweight; can grow despite GLP-1 worries
October 27, 2023 6:28 AM
ResMed (RMD) PT Lowered to $200 at RBC Capital
October 27, 2023 6:16 AM
Form 10-Q RESMED INC For: Sep 30
October 27, 2023 6:04 AM
ResMed (RMD:AU) (RMD) PT Lowered to AUD29 at Citi
October 27, 2023 5:44 AM
ResMed (RMD) Tops Q1 EPS by 3c
October 26, 2023 4:33 PM
Form 8-K RESMED INC For: Oct 26
October 26, 2023 4:10 PM
ResMed (RMD:AU) (RMD) PT Lowered to AUD32.30 at Macquarie
October 25, 2023 11:25 AM
